NO20085332L - Duloksetinhydrogenklorid-formuleringer med forsinket frigivelse - Google Patents

Duloksetinhydrogenklorid-formuleringer med forsinket frigivelse

Info

Publication number
NO20085332L
NO20085332L NO20085332A NO20085332A NO20085332L NO 20085332 L NO20085332 L NO 20085332L NO 20085332 A NO20085332 A NO 20085332A NO 20085332 A NO20085332 A NO 20085332A NO 20085332 L NO20085332 L NO 20085332L
Authority
NO
Norway
Prior art keywords
hydrogen chloride
delayed release
duloxetine
chloride formulations
layer
Prior art date
Application number
NO20085332A
Other languages
English (en)
Inventor
Gershon Kolatkar
Erela Zisman
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20085332L publication Critical patent/NO20085332L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formuleringer med forsinket frigivelse av duloksetinhydrogenklorid og fremgangsmåter for fremstilling av slike er beskrevet. En foretrukket formulering innbefatter en inert kjerne, et legemiddellag omfattende duloksetinhydrogenklorid, et skillelag og et enterisk lag som omfatter minst én av metakrylsyrekopolymer og hydroksypropylmetylcelluloseftalat.
NO20085332A 2006-05-22 2008-12-19 Duloksetinhydrogenklorid-formuleringer med forsinket frigivelse NO20085332L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80284906P 2006-05-22 2006-05-22
PCT/US2007/012387 WO2007139886A2 (en) 2006-05-22 2007-05-22 Duloxetine hydrochloride delayed release formulations

Publications (1)

Publication Number Publication Date
NO20085332L true NO20085332L (no) 2008-12-19

Family

ID=38779216

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085332A NO20085332L (no) 2006-05-22 2008-12-19 Duloksetinhydrogenklorid-formuleringer med forsinket frigivelse

Country Status (12)

Country Link
US (1) US20070292511A1 (no)
EP (1) EP1919467A2 (no)
JP (1) JP2009538315A (no)
KR (1) KR20090005237A (no)
CN (1) CN101448493A (no)
BR (1) BRPI0711606A2 (no)
CA (1) CA2651716A1 (no)
IL (1) IL194877A0 (no)
MX (1) MX2008014758A (no)
NO (1) NO20085332L (no)
RU (1) RU2008148547A (no)
WO (1) WO2007139886A2 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175935A1 (en) * 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
WO2009004649A2 (en) * 2007-05-21 2009-01-08 Sun Pharmaceutical Industries Limited Enteric coated pharmaceutical compositions
GB0712220D0 (en) * 2007-06-23 2007-08-01 Arrow Int Ltd Duloxetine formulation
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
EP2182929A2 (en) * 2007-07-13 2010-05-12 Synthon B.V. Duloxetine formulations
AU2009206204B2 (en) * 2008-01-25 2015-03-19 Alphapharm Pty Ltd Delayed release pharmaceutical composition of duloxetine
WO2009118756A2 (en) * 2008-03-24 2009-10-01 Lupin Limited Delayed release compositions of duloxetine
US20110150942A1 (en) * 2008-06-13 2011-06-23 Natalija Zajc Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
EP2133072A1 (en) 2008-06-13 2009-12-16 KRKA, D.D., Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
ES2376095B1 (es) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. Pellets entéricos de duloxetina.
WO2010078878A1 (en) * 2009-01-12 2010-07-15 Synthon B.V. Duloxetine formulations
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
CN102869349A (zh) * 2010-03-09 2013-01-09 阿尔科米斯制药爱尔兰有限公司 耐酒精的肠溶药物组合物
EP2377525A1 (en) 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
WO2013045352A1 (de) * 2011-09-30 2013-04-04 Basf Se Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
BR112015010704B8 (pt) * 2012-11-12 2022-06-14 New Jersey Inst Technology Partícula compósita, e, processo para preparar uma partícula compósita
CN103127023B (zh) * 2013-03-01 2014-08-27 河北天成药业股份有限公司 一种盐酸度洛西汀肠溶片及其制备方法
CN103211777A (zh) * 2013-03-31 2013-07-24 北京万全阳光医学技术有限公司 一种盐酸度洛西汀的药物制剂及其制备的方法
CN103393615B (zh) * 2013-07-24 2015-07-15 海南华益泰康药业有限公司 一种度洛西汀肠溶小丸及其制备方法
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
JP6815109B2 (ja) * 2016-06-23 2021-01-20 キョーリンリメディオ株式会社 デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物
JP6866136B2 (ja) * 2016-11-30 2021-04-28 共和薬品工業株式会社 デュロキセチン塩酸塩を含む口腔内崩壊錠
US9839626B1 (en) 2016-12-14 2017-12-12 Sun Pharmaceutical Industries Limited Duloxetine sprinkles
JP2018154590A (ja) * 2017-03-17 2018-10-04 沢井製薬株式会社 デュロキセチン腸溶性顆粒およびデュロキセチン腸溶性製剤
JP7072431B2 (ja) * 2017-04-14 2022-05-20 富士化学工業株式会社 錠剤及びその製造方法
JP6972674B2 (ja) * 2017-06-06 2021-11-24 ニプロ株式会社 経口医薬製剤
JP2019081753A (ja) * 2017-10-30 2019-05-30 大原薬品工業株式会社 デュロキセチン塩酸塩の溶出性が改善された腸溶性製剤
EP3749289A4 (en) * 2018-02-06 2021-11-17 Robert Niichel MULTI-PARTICULAR PRODUCT CONTAINING ACTIVE PHARMACEUTICAL OR PROBIOTIC SUBSTANCES
CA3104459A1 (en) * 2018-06-22 2019-12-26 Qualicaps Co., Ltd. Enteric hard capsule
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒
PT3628311T (pt) * 2018-09-27 2021-02-09 Inibsa Ginecologia S A Um processo para a preparação de uma forma de dosagem oral, de unidade múltipla de libertação modificada, de sucinato de doxilamina e cloridrato de piridoxina
CN112168797A (zh) * 2020-10-14 2021-01-05 宁波高新区美诺华医药创新研究院有限公司 度洛西汀药物组合物
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
JP2007517038A (ja) * 2003-12-30 2007-06-28 ドクター レディズ ラボラトリーズ リミテッド 薬学的組成物
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
EP1904039A2 (en) * 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions

Also Published As

Publication number Publication date
WO2007139886A3 (en) 2008-03-13
CA2651716A1 (en) 2007-12-06
BRPI0711606A2 (pt) 2012-02-14
RU2008148547A (ru) 2010-06-27
EP1919467A2 (en) 2008-05-14
CN101448493A (zh) 2009-06-03
WO2007139886A2 (en) 2007-12-06
IL194877A0 (en) 2009-08-03
KR20090005237A (ko) 2009-01-12
JP2009538315A (ja) 2009-11-05
MX2008014758A (es) 2009-01-19
US20070292511A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
NO20085332L (no) Duloksetinhydrogenklorid-formuleringer med forsinket frigivelse
NO20076288L (no) Farmasoytiske sammensetninger innbefattende imatinib og et frigivningssinkende middel
EA201892836A1 (ru) Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
NO20090346L (no) Pyrazolderivater som inhibitorer av cytokrom P450
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
WO2009088414A3 (en) Oral pharmaceutical dosage forms
DK2032123T3 (da) Anvendelse af en hydrofil matrix indeholdende et polyacrylsurederivat, en celluloseether og en disintegrant til fremstilling af et medikament til behandling af kvindelige kønslidelser
IL184126A0 (en) Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20074848L (no) Farmasoytiske former med forbedrede farmakokinetiske egenskaper
NO20100250L (no) Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav
DK1940364T4 (da) Kapselformulering af pirfenidon og farmaceutisk acceptable excipienser
DK1940366T3 (da) Blöde kapsler, der omfatter palonosetron-hydrochlorid, som har forbedret stabilitet og biotilgængelighed
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
WO2009058950A3 (en) Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
PL1931316T3 (pl) Kompozycje farmaceutyczne o kontrolowanym uwalnianiu dla leków labilnych kwasowo
DK1789405T3 (da) Nye enantiomerrene betaagonister, fremgangsmåder til deres fremstilling og deres anvendelse som lægemiddel
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
EP1796641A4 (en) NEW FORMULATION, OMEPRAZOL ANTAZIDA COMPLEX WITH IMMEDIATE RELEASE FOR THE RAPID AND CONTINUOUS SUPPRESSION OF MAGIC ACID
WO2009043926A3 (en) Oral fast disintegrating tablets
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
WO2009090484A3 (en) Mesalazine tablet
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application